Samsung Bioepis is off to a smooth start this year with a sharp rise in its biosimilar sales.

According to the Korea Financial Supervisory Service, Samsung Bioepis recorded ₩199.1 in Q1 sales this year, a 19.4% increase compared to the same quarter of the previous year. Also, the company’s net profit increased 11.5% to ₩31.9 billion.

This is the largest amount of sales ever made by the company in the first quarter. However, compared to the ₩271 billion in Q3 and ₩221.8 billion in Q4 it had made last year, the growth rate seems to have slowed down somewhat.

In Q3 last year, the company had recorded its largest-ever sales with the milestone it received w